TY - JOUR
T1 - Islet Cell Tumors of the Pancreas
AU - Amin, Sunil
AU - Kim, Michelle Kang
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Islet cell tumors of the pancreas, also known as pancreatic neuroendocrine tumors, constitute less than 5% of pancreatic tumors, and 7% of all neuroendocrine tumors. Most are non-functional, and patients often present with metastatic disease. Functional tumors present with distinct clinical syndromes. Accurate staging is critical as surgery is both the cornerstone of treatment, and the only hope for cure. Medical management involves treating the manifestations of hormonal excess, and using somatastatin analogues when appropriate. Systemic chemotherapy, targeted molecular therapy, and peptide receptor radiotherapy may be used for refractory disease in lieu of or as an adjunct to surgery.
AB - Islet cell tumors of the pancreas, also known as pancreatic neuroendocrine tumors, constitute less than 5% of pancreatic tumors, and 7% of all neuroendocrine tumors. Most are non-functional, and patients often present with metastatic disease. Functional tumors present with distinct clinical syndromes. Accurate staging is critical as surgery is both the cornerstone of treatment, and the only hope for cure. Medical management involves treating the manifestations of hormonal excess, and using somatastatin analogues when appropriate. Systemic chemotherapy, targeted molecular therapy, and peptide receptor radiotherapy may be used for refractory disease in lieu of or as an adjunct to surgery.
KW - Islet cell tumor
KW - Pancreas
KW - Pancreas cancer
KW - Pancreatic neuroendocrine tumors (PNET)
KW - Targeted molecular therapy
UR - http://www.scopus.com/inward/record.url?scp=84958166640&partnerID=8YFLogxK
U2 - 10.1016/j.gtc.2015.10.007
DO - 10.1016/j.gtc.2015.10.007
M3 - Review article
C2 - 26895682
AN - SCOPUS:84958166640
SN - 0889-8553
VL - 45
SP - 83
EP - 100
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
IS - 1
ER -